Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response

Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging. Directly monitoring mutational disease burden may be useful, but is not currently included in MDS response criteria, and the correlation of mutational burden and traditional response endpoints is not comp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2025-01, Vol.39 (1), p.166-177
Hauptverfasser:	Jacoby, Meagan A, Duncavage, Eric D, Khanna, Ajay, Chang, Gue Su, Nonavinkere Srivatsan, Sridhar, Miller, Christopher A, Gao, Feng, Robinson, Josh, Shao, Jin, Fulton, Robert S, Fronick, Catrina C, O'Laughlin, Michelle, Heath, Sharon E, Brendel, Kimberly, Chavez, Monique, DiPersio, John F, Abboud, Camille N, Stockerl-Goldstein, Keith, Westervelt, Peter, Cashen, Amanda, Pusic, Iskra, Oh, Stephen T, Welch, John S, Wells, Denise A, Loken, Michael R, Uy, Geoffrey L, Walter, Matthew J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Aplasia Blast Crisis - genetics Blast Crisis - pathology Bone marrow Clinical trials Female Gene sequencing Genomes High-Throughput Nucleotide Sequencing - methods Humans Male Middle Aged Monitoring Mutation Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - pathology Neoplasia Next-generation sequencing Patients Prognosis Prospective Studies Remission Remission (Medicine) Remission Induction Telemedicine Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!